Design and development of loteprednol etabonate nanodispersion for ophthalmic drug delivery
Keywords:
Loteprednol Etabonate (LE), Nanodispersion, Post-operative inflammation, OphthalmicAbstract
Postoperative inflammation after cataract surgery can prolong visual recovery time, increase the treatment burden and elevate the risk of poor visual outcomes. Corticosteroids are potent anti-inflammatory agents that have been used successfully for decades to treat ocular inflammation. However, the side effects associated with topical corticosteroids including increased intraocular pressure, risk of cataract formation after long-term use, and decreased resistance to infection are of major concerns. Amongst the available topical corticosteroids Loteprednol Etabonate (LE), an ester-based corticosteroid has been selected for studies. The aim of the present study was to develop Loteprednol etabonate loaded nanodispersion for treatment of steroid responsive inflammatory conditions of eye with objectives of reducing the frequency of administration and increasing the solubility of drug. Non-solvent method was used to formulate nanodispersion. The formulation was assessed for particle size and polydispersity index, drug content, surface morphology, isotonicity, test of sterility, in-vitro & ex-vivo release. Mean particle size and PI of optimized batch was found to be 50±10nm and PI 0.2±0.1. No microbial growth was observed in optimized formulation during sterility testing and the formulation was isotonic when compared with marketed formulation and plain blood cells.
Downloads
References
Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796
Bodor, N. and Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. The AAPS journal. 2005, 7(4), E820-E833.
Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) November 2003 ICH Revision 2.
https://www.rxlist.com/lotemax-drug.htm#dosage
Indian Pharmacopoeia, Vol. 2, Ministry of Health and Family Welfare, Government of India, New Delhi, 1996, A117- A147.
Leong, W.F.; Lai, O.M.; Long, K.; Man, Y.B.C.; Misran, M. and Tan, C.P. Preparation and characterisation of water-soluble phytosterol nanodispersions. Food Chemistry. 2011, 129(1), 77-83.
Patel, N.; Nakrani, H.; Raval, M. and Sheth, N. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug delivery. 2016, 23(9), 3712-3723.
Pepić, I.; Hafner, A.; Lovrić, J.; Pirkić, B. and Filipović-Grcčić, J. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. Journal of pharmaceutical sciences. 2010,99(10),4317-4325.
Porela-Tiihonen, S.; Kaarniranta, K.; Kokki, M.; Purhonen, S. and Kokki, H. A prospective study on postoperative pain after cataract surgery. Clinical ophthalmology (Auckland, NZ). 2013,7,1429.
Shah, T.J.; Conway, M.D. and Peyman, G.A. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy. Clinical Ophthalmology (Auckland, NZ). 2018, 12, 2223.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Walters, T.; Bafna, S.; Vold, S.; Wortz, G.; Harton, P.; Levenson, J.; Hovanesia, J.; Mah, F.; Gira, J.; Vroman, D. and Sampson, R. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies. J Clin Exp Ophthalmol. 2016, 7(4).
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
